Study Comparing Surgenex® PelloGraft and SanoGraft® for Wound Healing
This study is looking at how well two products, Surgenex® PelloGraft and SanoGraft®, help heal wounds compared to standard care. Surgenex® PelloGraft is being tested for diabetic foot ulcers (wounds on the feet of people with diabetes), and SanoGraft® is being tested for venous leg ulcers (wounds on the legs due to poor blood flow). The goal is to see if these products can lead to complete wound healing (100% epithelialization) within 12 weeks for diabetic foot ulcers or 16 weeks for venous leg ulcers. You might be able to join if you are at least 18 years old and have a diabetic foot ulcer or a venous leg ulcer of a certain size. The study status is currently unclear.
- Study design
- This interventional study plans to enroll 180 participants. It compares the new treatments to standard care.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures complete healing at 12 weeks for diabetic foot ulcers or 16 weeks for venous leg ulcers.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
At a glance
Conditions
Where it's being run
2 sites across 2 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- 100% epithelialization12 weeks (DFU) or 16 weeks (VLU)
100% epithelialization of wound within 12 weeks (DFU) or 16 weeks (VLU) of initial treatment application. Wound closure is complete with confirmation of 100% epithelialization, no drainage, and no need for additional dressings.